Is finerenone therapy cost-effective for patients with chronic kidney disease and type 2 diabetes in England & Wales?
Finerenone therapy is considered cost-effective for patients with chronic kidney disease and type 2 diabetes in England and Wales.
Sensitivity and scenario analyses, including more frequent SGLT2 inhibitor use consistent with real-world data, indicate a robust ICER that remains within the bounds of what is typically considered cost-effective.
Cherney et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: